Targeting protein-protein and protein-nucleic acid interactions for Anti-HIV therapy

Current Pharmaceutical Design

Volumn 17, Issue 33, 2011, Pages 3713-3728

  Mori, Mattia ^a   Manetti, Fabrizio ^a   Botta, Maurizio ^a,b  

^a UNIVERSITY OF SIENA   (Italy)

^b Temple University   (United States)

Author keywords

AIDS; Entry; Gp120 CD4; HIV 1; Nucleocapsid protein NCp7; Protein nucleic acid interactions; Protein protein interactions; Reverse transcriptase dimerization

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BMS 663068; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CICHORIC ACID; DOUBLE STRANDED RNA; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; IBALIZUMAB; MARAVIROC; NBD 556; NBD 557; NCS 651016; NEF PROTEIN; NUCLEOCAPSID PROTEIN; PROTEIN P51; PROTEIN P66; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; ZINTEVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIANGIOGENIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CATALYSIS; CD4+ T LYMPHOCYTE; CELL GROWTH; CELL PROLIFERATION; CYTOTOXICITY; DIMERIZATION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC HETEROGENEITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MUTAGENESIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; VIRUS ATTACHMENT; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIMERIZATION; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; VIRAL PROTEINS;

EID: 82055192318     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798220972     Document Type: Article

References (152)

1. Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today 2005; 10 (23-24): 1607-10.
2. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1 (9): 727-30.
3. Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist. Updat 2003; 6 (5): 231-8.
4. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009; 12 (5): 476-81.
5. Cvijic ME, Yang WL, Chin KV. Cisplatin resistance in cyclic AMPdependent protein kinase mutants. Pharmacol Ther 1998, 78 (2): 115-28.
6. Austin CP. The impact of the completed human genome sequence on the development of novel therapeutics for human disease. Annu Rev Med 2004; 55: 1-13.
7. Batley J, Edwards D. Genome sequence data: management, storage, and visualization. Biotechniques 2009; 46 (5): 333-4, 336.
8. Bentley DR. Decoding the human genome sequence. Hum. Mol Genet 2000; 9 (16): 2353-2358.
9. Grenet O. Significance of the human genome sequence to drug discovery. Pharmacogenomics. J 2001; 1 (1): 11-2.
10. Hakes L, Pinney JW, Robertson DL, Lovell SC. Protein-protein interaction networks and biology--what's the connection? Nat Biotechnol 2008; 26 (1): 69-72.
11. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3 (4): 301-17.
12. Ryan DP, Matthews JM. Protein-protein interactions in human disease. Curr Opin Struct Biol 2005; 15 (4): 441-6.
13. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007; 450 (7172): 1001-9.
14. Van MB, Busschots K, Vandekerckhove L, Christ F, Debyser Z. Cellular co-factors of HIV-1 integration. Trends Biochem Sci 2006; 31 (2): 98-105.
15. Henderson D, Hurley LH. Specific targeting of protein-DNA complexes by DNA-reactive drugs (+)-CC-1065 and pluramycins. J Mol Recognit 1996, 9 (2): 75-87.
16. Moras D, Poterszman A. Getting into the major groove. Protein- RNA interactions. Curr Biol 1996, 6 (5): 530-2.
17. Yang J, Yuan YA. A structural perspective of the protein-RNA interactions involved in virus-induced RNA silencing and its suppression. Biochim Biophys Acta 2009; 1789 (9-10): 642-52.
18. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J. Pharm Sci 2004; 93 (11): 2645-68.
19. Huther A, Dietrich U. The emergence of peptides as therapeutic drugs for the inhibition of HIV-1. AIDS Rev 2007; 9 (4) 208-17.
20. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem Int Ed Engl 2005; 44 (27): 4130-63.
21. Clackson T, Wells JA. A hot spot of binding energy in a hormonereceptor interface. Science 1995, 267 (5196): 383-6.
22. Archakov AI, Govorun VM, Dubanov AV, et al. Protein-protein interactions as a target for drugs in proteomics. Proteomics 2003; 3 (4): 380-91.
23. DeLano WL. Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 2002; 12 (1): 14-20.
24. Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996, 93 (1): 13-20.
25. White AW, Westwell AD, Brahemi G. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert. Rev Mol Med 2008; 10, e8.
26. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68 (9): 3421-8.
27. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003; 46 (20): 4259-64.
28. Tang G, Yang CY, Nikolovska-Coleska Z, et al. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. J Med Chem 2007; 50 (8): 1723-6.
29. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105 (10): 3933-8.
30. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303 (5659): 844-8.
31. Arendt Y, Bhaumik A, Del Conte R, Luchinat C, Mori M, Porcu M. Fragment docking to S100 proteins reveals a wide diversity of weak interaction sites. ChemMedChem 2007; 2 (11): 1648-54.
32. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41- mediated virus entry. Nat Med 1998, 4 (11): 1302-7.
33. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004; 3 (3): 215-25.
34. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother 2005; 49 (11): 4721-32.
35. Tachedjian G, Goff SP. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr Opin Investig Drugs 2003; 4 (8): 966-73.
36. Richter SN, Frasson I, Palu G. Strategies for inhibiting function of HIV-1 accessory proteins: a necessary route to AIDS therapy? Curr Med Chem 2009; 16 (3): 267-86.
37. Cen S, Peng ZG, Li XY, et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol Chem 2010; 285 (22): 16546-52.
38. Christ F, Voet A, Marchand A, et al. Rational design of smallmolecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010; 6 (6): 442-8.
39. Este JA, Telenti A. HIV entry inhibitors. Lancet 2007; 370 (9581): 81-8.
40. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 2010; 85 (1): 91-100.
41. Vermeire K, Schols D. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert. Opin Investig Drugs 2005; 14 (10): 1199-212.
42. Vermeire K, Schols D, Bell TW. Inhibitors of HIV infection via the cellular CD4 receptor. Curr Med Chem 2006; 13 (7): 731-43.
43. Liu S, Wu S, Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des 2007; 13 (2): 143-62.
44. McKinnell JA, Saag MS. Novel drug classes: entry inhibitors[enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]. Curr Opin HIV. AIDS 2009; 4 (6): 513-7.
45. Chen RY, Kilby JM, Saag MS. Enfuvirtide. Expert. Opin Investig Drugs 2002; 11 (12): 1837-43.
46. Makinson A, Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV. AIDS 2009; 4 (2): 150-8.
47. Manfredi R, Sabbatani S. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr Med Chem 2006; 13 (20): 2369-84.
48. Kadow J, Wang HG, Lin PF. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr Opin Investig Drugs 2006; 7 (8): 721-6.
49. Lin PF, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003; 100 (19): 11013-18.
50. Diskin R, Marcovecchio PM, Bjorkman PJ. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti- CD4 polyreactivity. Nat Struct Mol Biol 2010; 17 (5): 608-13.
51. Huang CC, Tang M, Zhang MY, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310 (5750): 1025-8.
52. Pancera M, Majeed S, Ban YE, et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 2010; 107 (3): 1166-71.
53. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393 (6686): 648-59.
54. Kwong PD, Wyatt R, Majeed S, et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000; 8 (12): 1329-39.
55. Allaway GP, Davis-Bruno KL, Beaudry GA, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 1995; 11 (5): 533-9.
56. Jacobson JM, Lowy I, Fletcher CV, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis 2000; 182 (1): 326-9.
57. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIVinfected adults. J. Infect. Dis 2008; 198 (9): 1345-52.
58. Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol 2001; 75 (2): 579-88.
59. Dimitrov A. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Curr Opin Investig Drugs 2007; 8 (8): 653-61.
60. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis 2004; 189 (2): 286-91.
61. Wang T, Yin Z, Zhang Z, et al. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4- benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects. J Med Chem 2009; 52 (23): 7778-87.
62. Guo Q, Ho HT, Dicker I, et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003; 77 (19): 10528-36.
63. Ho HT, Fan L, Nowicka-Sans B, et al. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol 2006; 80 (8): 4017-25.
64. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11 (14): 1805-43.
65. Clanton DJ, Buckheit RW., Jr, Terpening SJ, et al. Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res 1995, 27 (4): 335-54.
66. Finch PW, Yee LK, Chu MY, et al. Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative. Pharmacology 1997, 55 (6): 269-78.
67. Manetti F, Cappello V, Botta M, et al. Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor. Bioorg. Med Chem 1998, 6 (7): 947-58.
68. Quesada AR, Munoz-Chapuli R, Medina MA. Anti-angiogenic drugs: from bench to clinical trials. Med Res. Rev 2006; 26 (4): 483-530.
69. Lederman S, Bergmann JE, Cleary AM, Yellin MJ, Fusco PJ, Chess L. Sulfated polyester interactions with the CD4 molecule and with the third variable loop domain (v3) of gp120 are chemically distinct. AIDS Res. Hum. Retroviruses 1992, 8 (9): 1599-610.
70. Leydet A, Jeantet-Segonds C, Bouchitte C, et al. Polyanion inhibitors of human immunodeficiency virus and other viruses. 6. Micelle-like anti-HIV polyanionic compounds based on a carbohydrate core. J. Med Chem 1997, 40 (3): 350-6.
71. Leydet A, Moullet C, Roque JP, et al. Polyanion inhibitors of HIV and other viruses. 7. Polyanionic compounds and polyzwitterionic compounds derived from cyclodextrins as inhibitors of HIV transmission. J. Med Chem 1998, 41 (25): 4927-32.
72. Mohan P, Wong MF, Verma S, Huang PP, Wickramasinghe A, Baba M. Structure-activity relationship studies with symmetric naphthalenesulfonic acid derivatives. Synthesis and influence of spacer and naphthalenesulfonic acid moiety on anti-HIV-1 activity. J. Med Chem 1993, 36 (14) 1996-2003.
73. Manetti F, Corelli F, Mongelli N, Borgia AL, Botta M. Research on anti-HIV-1 agents. Investigation on the CD4-Suradista binding mode through docking experiments. J. Comput. Aided Mol Des 2000; 14 (4): 355-68.
74. Jiang S, Lin K, Zhang L, Debnath AK. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods 1999, 80 (1): 85-96.
75. Debnath AK, Radigan L, Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med Chem 1999, 42 (17): 3203-9.
76. Wang H, Qi Z, Guo A, et al. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob. Agents Chemother 2009; 53 (12): 4987-98.
77. Armand-Ugon M, Clotet-Codina I, Tintori C, Manetti F, Clotet B, Botta M, Este JA. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology 2005; 343 (1): 141-9.
78. Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. An update in the development of HIV entry inhibitors. Curr Top. Med Chem 2007; 7 (13): 1273-9.
79. Zhao Q, Ma L, Jiang S, et al. Identification of N-phenyl-N'-(2,2,6,6- tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005; 339 (2): 213-25.
80. Brower ET, Schon A, Freire E. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Biochemistry 2010; 49 (11): 2359-67.
81. Madani N, Schon A, Princiotto AM, et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008; 16 (11): 1689-701.
82. Caporuscio F, Tafi A, Gonzalez E, Manetti F, Este JA, Botta M. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120- CD4 protein-protein interactions. Bioorg. Med Chem Lett 2009; 19 (21): 6087-91.
83. Green DV. Virtual screening of virtual libraries. Prog. Med Chem 2003; 41: 61-97.
84. Guido RV, Oliva G, Andricopulo AD. Virtual screening and its integration with modern drug design technologies. Curr Med Chem 2008; 15 (1): 37-46.
85. Moncunill G, Armand-Ugon M, Clotet-Codina I, et al. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026. Mol Pharmacol 2008; 73 (4): 1264-73.
86. Moncunill G, Armand-Ugon M, Pauls E, Clotet B, Este JA. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008; 22 (1): 23-31.
87. Vivet-Boudou V, Didierjean J, Isel C, Marquet R. Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell Mol Life Sci 2006; 63 (2): 163-86.
88. Restle T, Muller B, Goody RS. RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett 1992 300 (1): 97-100.
89. Restle T, Pawlita M, Sczakiel G, Muller B, Goody RS. Structurefunction relationships of HIV-1 reverse transcriptase determined using monoclonal antibodies. J Biol Chem 1992, 267 (21): 14654-61.
90. Divita G, Rittinger K, Geourjon C, Deleage G, Goody RS. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J Mol Biol 1995, 245 (5): 508-21.
91. Tachedjian G, Aronson HE, de los SM, Seehra J, McCoy JM, Goff SP. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J Mol Biol 2003; 326 (2): 381-96.
92. Mulky A, Sarafianos SG, Jia Y, Arnold E, Kappes JC. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. J Mol Biol 2005; 349 (4): 673-84.
93. Cullen MD, Ho WC, Bauman JD, et al. Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase. J. Med Chem 2009; 52 (20): 6467-73.
94. Lansdon EB, Brendza KM, Hung M, et al. Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design. J Med Chem 2010.
95. Ren J, Esnouf R, Garman E, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995, 2 (4): 293-302.
96. Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G. A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. J Biol Chem 2009; 284 (1): 254-64.
97. Divita G, Restle T, Goody RS, Chermann JC, Baillon JG. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. Biol Chem 1994; 269 (18): 13080-3.
98. Morris MC, Robert-Hebmann V, Chaloin L, et al. new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. J Biol Chem 1999, 274 (35): 24941-6.
99. Baillon JG, Nashed NT, Kumar A, Wilson SH, Jerina DM. A leucine zipper-like motif may mediate HIV reverse transcriptase subunit binding. New Biol 1991, 3 (10): 1015-1019.
100. Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa MJ, Parniak MA. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4-amino-2,2 -dioxo-1,2 - oxathiole-5,3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-Dribofuranosyl]]]-3-ethylthy mine. Biochemistry 2000; 39 (6): 1427-33.
101. Sluis-Cremer N, Hamamouch N, San FA, Velazquez S, Balzarini J, Camarasa MJ. Structure-activity relationships of [2',5'-bis-O-(tertbutyldimethylsilyl)- beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. J Med Chem 2006; 49 (16): 4834-41.
102. Das K, Bauman JD, Rim AS, et al. Crystal structure of tertbutyldimethylsilyl- spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. J Med Chem 2011; 54 (8): 2727-37.
103. Sluis-Cremer N, Arion D, Parniak MA. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 2002; 62 (2): 398-405.
104. Grohmann D, Corradi V, Elbasyouny M, et al. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. Chembiochem 2008; 9 (6): 916-22.
105. Emert-Sedlak L, Kodama T, Lerner EC, et al. Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol 2009; 4 (11): 939-947.
106. Roques BP, Morellet N, de RH, Demene H, Schueler W, Jullian N. Structure, biological functions and inhibition of the HIV-1 proteins Vpr and NCp7. Biochimie 1997; 79 (11): 673-80.
107. McLendon G, Hull H, Larkin K, Chang W. Metal binding to the HIV nucleocapsid peptide. J. Biol Inorg. Chem 1999; 4 (2): 171-4.
108. Morellet N, de Rocquigny H, Mely Y, et al. Conformational behaviour of the active and inactive forms of the nucleocapsid NCp7 of HIV-1 studied by 1H NMR. J. Mol Biol 1994; 235 (1): 287-301.
109. Xi X, Sun Y, Karim CB, Grigoryants VM, Scholes CP. HIV-1 nucleocapsid protein NCp7 and its RNA stem loop 3 partner: rotational dynamics of spin-labeled RNA stem loop 3. Biochemistry 2008; 47 (38): 10099-110.
110. Goldschmidt V, MIller Jenkins ML, de Rocquigny H, Darlix JL, Mely Y. The nucleocapsid protein of HIV-1 as a promising therapeuic target for antiviral drugs. HIV Ther 2010; 4 (2): 179-98.
111. Remy E, de Rocquigny H, Petitjean P, et al. The annealing of tRNA3Lys to human immunodeficiency virus type 1 primer binding site is critically dependent on the NCp7 zinc fingers structure. J. Biol Chem 1998, 273 (9): 4819-22.
112. Beltz H, Clauss C, Piemont E, et al. Structural determinants of HIV-1 nucleocapsid protein for cTAR DNA binding and destabilization, and correlation with inhibition of self-primed DNA synthesis. J Mol Biol 2005; 348 (5): 1113-26.
113. Bombarda E, Ababou A, Vuilleumier C, et al. Time-resolved fluorescence investigation of the human immunodeficiency virus type 1 nucleocapsid protein: influence of the binding of nucleic acids. Biophys J 1999, 76 (3): 1561-70.
114. Mely Y, Piemont E, Sorinas-Jimeno M, et al. Structural and dynamic characterization of the aromatic amino acids of the human immunodeficiency virus type I nucleocapsid protein zinc fingers and their involvement in heterologous tRNA(Phe) binding: a steady-state and time-resolved fluorescence study. Biophys J 1993, 65 (4): 1513-22.
115. Cristofari G, Darlix JL. The ubiquitous nature of RNA chaperone proteins. Prog. Nucleic Acid Res. Mol Biol 2002; 72: 223-68.
116. Levin JG, Guo J, Rouzina I, Musier-Forsyth K. Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog Nucleic Acid Res Mol Biol 2005; 80: 217-86.
117. Rein A, Henderson LE, Levin JG. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci 1998, 23 (8): 297-301.
118. Bombarda E, Roques BP, Mely Y, Grell E. Mechanism of zinc coordination by point-mutated structures of the distal CCHC binding motif of the HIV-1 NCp7 protein. Biochemistry 2005; 44 (19): 7315-25.
119. Houzet L, Morichaud Z, Didierlaurent L, Muriaux D, Darlix JL, Mougel M. Nucleocapsid mutations turn HIV-1 into a DNAcontaining virus. Nucleic Acids Res 2008; 36 (7): 2311-9.
120. Stote RH, Kellenberger E, Muller H, et al. Structure of the His44 --> Ala single point mutant of the distal finger motif of HIV-1 nucleocapsid protein: a combined NMR, molecular dynamics simulation, and fluorescence study. Biochemistry 2004; 43 (24): 7687-97.
121. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007; 6 (12): 1001-18.
122. de Rocquigny H, Petitjean P, Tanchou V, et al. The zinc fingers of HIV nucleocapsid protein NCp7 direct interactions with the viral regulatory protein Vpr. J. Biol Chem 1997, 272 (49): 30753-9.
123. Druillennec S, Caneparo A, de Rocquigny H, Roques BP. Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. J. Biol Chem 1999, 274 (16): 11283-8.
124. Lingappa JR, Dooher JE, Newman MA, Kiser PK, Klein KC. Basic residues in the nucleocapsid domain of Gag are required for interaction of HIV-1 gag with ABCE1 (HP68), a cellular protein important for HIV-1 capsid assembly. J. Biol Chem 2006; 281 (7): 3773-84.
125. Popov S, Popova E, Inoue M, Gottlinger HG. Human immunodeficiency virus type 1 Gag engages the Bro1 domain of ALIX/AIP1 through the nucleocapsid. J. Virol 2008; 82 (3): 1389-98.
126. Jenkins LM, Byrd JC, Hara T, et al. Studies on the mechanism of inactivation of the HIV-1 nucleocapsid protein NCp7 with 2- mercaptobenzamide thioesters. J. Med Chem 2005; 48 (8): 2847-58.
127. Miller Jenkins LM, Hara T, Durell SR, et al. Specificity of acyl transfer from 2-mercaptobenzamide thioesters to the HIV-1 nucleocapsid protein. J. Am. Chem Soc 2007; 129 (36): 11067-78.
128. Held DM, Kissel JD, Patterson JT, Nickens DG, Burke DH. HIV-1 inactivation by nucleic acid aptamers. Front Biosci 2006; 11: 89-112.
129. Jeong YY, Kim SH, Jang SI, You JC. Examination of specific binding activity of aptamer RNAs to the HIV-NC by using a cellbased in vivo assay for protein-RNA interaction. BMB. Rep 2008; 41 (7): 511-5.
130. Kim SJ, Kim MY, Lee JH, You JC, Jeong S. Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem Biophys Res. Commun 2002; 291 (4): 925-31.
131. Dietz J, Koch J, Kaur A, et al. Inhibition of HIV-1 by a peptide ligand of the genomic RNA packaging signal Psi. ChemMedChem 2008; 3 (5): 749-55.
132. Raja C, Ferner J, Dietrich U, et al tryptophan-rich hexapeptide inhibits nucleic acid destabilization chaperoned by the HIV-1 nucleocapsid protein. Biochemistry 2006; 45 (30): 9254-9265.
133. Capalbo G, Muller-Kuller T, Dietrich U, Hoelzer D, Ottmann OG, Scheuring UJ. Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression. Retrovirology 2010; 7: 26.
134. Cruceanu M, Stephen AG, Beuning PJ, Gorelick RJ, Fisher RJ, Williams MC. Single DNA molecule stretching measures the activity of chemicals that target the HIV-1 nucleocapsid protein. Anal. Biochem 2006; 358 (2): 159-70.
135. Stephen AG, Worthy KM, Towler E, et al. Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity. Biochem Biophys Res. Commun 2002; 296 (5): 1228-37.
136. de Rocquigny H, Shvadchak V, Avilov S, et al. Targeting the viral nucleocapsid protein in anti-HIV-1 therapy. Mini. Rev Med Chem 2008; 8 (1): 24-35.
137. Shvadchak V, Sanglier S, Rocle S, et al. Identification by high throughput screening of small compounds inhibiting the nucleic acid destabilization activity of the HIV-1 nucleocapsid protein. Biochimie 2009; 91 (7): 916-23.
138. Bourbigot S, Ramalanjaona N, Boudier C, et al. How the HIV-1 nucleocapsid protein binds and destabilises the (-)primer binding site during reverse transcription. J. Mol Biol 2008; 383 (5): 1112-28.
139. De Guzman RN, Wu ZR, Stalling CC, Pappalardo L, Borer PN, Summers MF. Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element. Science 1998, 279 (5349): 384-8.
140. Marco E, Gago F. Overcoming the inadequacies or limitations of experimental structures as drug targets by using computational modeling tools and molecular dynamics simulations. ChemMedChem 2007; 2 (10): 1388-401.
141. Mori M, Dietrich U, Manetti F, Botta M. Molecular dynamics and DFT study on HIV-1 nucleocapsid protein-7 in complex with viral genome. J. Chem Inf. Model 2010; 50 (4): 638-50.
142. Mori M, Manetti F, Botta M. Predicting the binding mode of known NCp7 inhibitors to facilitate the design of novel modulators. J. Chem Inf. Model 2011; 51 (2): 446-54.
143. Rang H.P, Dale M.M, Ritter J.M, Flower R.J. Rang and Dale's Pharmacology (6th Edition ed.); Philadelphia 2007.
144. Bannwarth L, Rose T, Dufau L, et al. Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases. Biochemistry 2009; 48 (2): 379-87.
145. Babe LM, Pichuantes S, Craik CS. Inhibition of HIV protease activity by heterodimer formation. Biochemistry 1991, 30 (1): 106-11.
146. Zhang ZY, Poorman RA, Maggiora LL, Heinrikson RL, Kezdy FJ. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol Chem 1991, 266 (24): 15591-94.
147. Zutshi R, Franciskovich J, Shultz M, et al. Targeting the dimerization interface of HIV-1 protease: Inhibition with crosslinked interfacial peptides. Journal of the American Chemical Society 1997, 119 (21): 4841-5.
148. Bouras A, Boggetto N, Benatalah Z, de RE, Sicsic S, Reboud- Ravaux M. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J. Med Chem 1999, 42 (6): 957-62.
149. Merabet N, Dumond J, Collinet B, et al. New constrainedmolecular tongs designed to dissociate HIV-1 protease dimer. J. Med Chem 2004; 47 (25): 6392-400.
150. Song M, Rajesh S, Hayashi Y, Kiso Y. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg. Med Chem Lett 2001; 11 (18): 2465-8.
151. Bannwarth L, Kessler A, Pethe S, et al. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization. J. Med Chem 2006; 49 (15): 4657-64.
152. Vidu A, Dufau L, Bannwarth L, et al. Toward the first nonpeptidic molecular tong inhibitor of wild-type and mutated HIV-1 protease dimerization. ChemMedChem 2010; 5 (11): 1899-906.